StockDuty ← Dashboard Oct 05, 2026 07:34 PM ET
SignalFDA/Bio

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell

Epcoritamab plus R-CHOP shows statistically significant progression-free survival improvement in newly diagnosed DLBCL.

What happened: Genmab and AbbVie reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients with an IPI score of 2 to 5. Key numbers: Risk of disease progression or death reduced by 51% (HR 0.49 [95% CI 0.36, Why it matters: The companies said this is the first Phase 3 study of a bispecific antibody combination to show a statistically significant PFS improvement in frontline DLBCL, and they will engage global regulatory authorities based on the topline results.
Genmab and AbbVie reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients with an IPI score of 2 to 5.
The companies said this is the first Phase 3 study of a bispecific antibody combination to show a statistically significant PFS improvement in frontline DLBCL, and they will engage global regulatory authorities based on the topline results.
Sources